Please Note
We brought you to this page based on your search query. If this isn't what you are looking for, you can continue to Search Results for ""
The maximum number of items you can export is 3,000. Please reduce your list by using the filtering tool to the left.

You Browsed By:

You Searched For:

The product image can not be displayed.


North America

Mark Gray

Managing Director - US/Americas Corporate Finance

Tom Marshella
Managing Director - US/Americas Corporate Finance

Latin America

Susan Knapp
Managing Director - Regional Head Americas


Myriam Durand
Managing Director- EMEA Corporate Finance

Asia Pacific

Brian Cahill
Managing Director - Asia Pacific Corporates/Financial Institutions


The product image can not be displayed.

Research and analysis on public companies and their debt instruments.



  • 24 Nov 2015
    • Brazil’s weakening economy poses liquidity challenges for its companies
      Brazil’s rated companies, grappling with a deteriorating economy and tightening credit markets, have already cut costs and reduced capital spending to preserve cash. As the economy continues to deteriorate the liquidity challenges they face may become more acute, impacting some companies more than others…Full Report l Press Release
    • US poultry industry better equipped for next possible avian flu outbreak
      The US poultry industry is better positioned to handle the next possible wave of the avian flu, with any future outbreak and resulting earnings fallout likely to be less severe than previously amid improved biosecurity. The larger, more diversified food producers are best positioned to withstand segment earnings pressure in contrast to the more concentrated operators, which would likely face high earnings volatility…Full Report l Press Release
  • 23 Nov 2015
    • Pfizer’s merger with Allergan will strengthen its business, but shareholder payouts will lower its cash over time
      The acquisition will improve Pfizer’s scale, diversity and research pipeline, creating a global pharmaceutical powerhouse. It will also result in significant tax benefits for the company, providing Pfizer with efficient access to cash flows. However, this access will likely benefit shareholders via share repurchases, lowering the company’s available cash for unexpected operating setbacks or debt repayment... Full Report l Press Release
Please refine your search by Market Segment to get corresponding Rating Activity and Watchlist
Complete Your Profile
Please complete your profile before submitting your comments.
We're Sorry
    © 2015 Moody's Investors Service, Inc., Moody’s Analytics, Inc. and/or their affiliates and licensors. All rights reserved.
    Regional Sites: